MDR1 Gene Mutation in Dogs: Drug Safety and Welfare

The MDR1 (ABCB1) gene mutation causes hypersensitivity to many common drugs in affected breeds, creating serious welfare risks if not identified before treatment.

Key Facts

Collies, Australian Shepherds, and related breeds commonly carry the MDR1 mutation
The mutation reduces P-glycoprotein function, allowing drugs to accumulate in the brain
Common drugs including ivermectin, loperamide, and many chemotherapy agents cause toxicity
Genetic testing identifies affected and carrier dogs before adverse reactions occur
Drug alternatives exist for most affected medications but require mutation status knowledge

Welfare Considerations

MDR1 mutation welfare management is primarily preventive — identifying affected dogs before exposing them to toxic drugs. An unidentified MDR1-affected dog treated with ivermectin-based antiparasitics or loperamide can develop acute neurological toxicity including tremors, seizures, blindness, and death. Genetic testing is inexpensive and provides lifelong safety guidance. Veterinarians treating known MDR1-affected dogs use alternative drugs or adjusted dosing protocols. The welfare stakes of missing this diagnosis are high, making testing of all predisposed breeds a welfare imperative before any relevant drug exposure.

What You Can Do

Test all herding breed dogs for MDR1 status before any treatment requiring these drugs
Carry your dog's MDR1 test results to all veterinary appointments
Ensure all vets treating your dog know their MDR1 status
Never give ivermectin or related drugs to untested dogs of predisposed breeds
Check the Washington State University MDR1 drug list for your dog's breed